No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305
Shashi N. Kapadia(Cornell University), Bruce R. Schackman(Cornell University), Kenneth H. Mayer(Miriam Hospital), Raphael J. Landovitz(APLA Health), Adriana Andrade(Johns Hopkins University), Marybeth McCauley(Family Health International 360), Roy M. Gulick(New York University), Wairimu Chege(National Institutes of Health), Ying Qing Chen(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Chunyuan Wu, K. Rivet Amico(University of Cape Town), Timothy Wilkin(Cornell University)
Cited by 4
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891